Ligand Pharmaceuticals (LGND) Cash from Operations (2010 - 2026)
Ligand Pharmaceuticals (LGND) reported Cash from Operations of 48691000.0 for Q1 2026, up 291.36% on a YoY basis from 12441555.07 in Q1 2025, and up 6.05% sequentially from 45915000.0 in Q4 2025.
Ligand Pharmaceuticals (LGND) Cash from Operations (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 17 years of Cash from Operations data on file, last reported at 48691000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 291.36% year-over-year to 48691000.0; the trailing twelve-month figure through Mar 2026 stood at 123495000.0 (up 133.58% YoY), and the FY2025 full-year result was 49359000.0, down 49.14% from the prior year.
- Cash from Operations rose to 48691000.0 in Q1 2026, from 45915000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 53472000.0 in Q4 2022 to a low of 25445000.0 in Q1 2025.
- A 5-year average of 22501411.76 and a median of 18732000.0 in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations jumped 16336.59% in 2024 and plunged 235.84% in 2025, its largest moves.
- Tracing LGND's Cash from Operations over 5 years: stood at 53472000.0 in 2022, then tumbled by 84.92% to 8065000.0 in 2023, then surged by 253.02% to 28471000.0 in 2024, then jumped by 61.27% to 45915000.0 in 2025, then advanced by 6.05% to 48691000.0 in 2026.
- Business Quant data shows LGND's Cash from Operations at 48691000.0 in Q1 2026, 45915000.0 in Q4 2025, and 13090000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | 48.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.69 Mn |
| Mar 31, 2026 | 48.69 Mn |
| Dec 31, 2025 | 45.92 Mn |
| Dec 31, 2025 | 45.92 Mn |
| Sep 30, 2025 | 13.09 Mn |
| Sep 30, 2025 | 13.09 Mn |
| Jun 30, 2025 | 15.80 Mn |
| Jun 30, 2025 | 15.80 Mn |
| Mar 31, 2025 | -25.45 Mn |
| Mar 31, 2025 | -25.45 Mn |
| Dec 31, 2024 | 28.47 Mn |
| Dec 31, 2024 | 28.47 Mn |
| Sep 30, 2024 | 36.53 Mn |
| Sep 30, 2024 | 36.53 Mn |
| Jun 30, 2024 | 13.31 Mn |
| Jun 30, 2024 | 13.31 Mn |
| Mar 31, 2024 | 18.73 Mn |
| Mar 31, 2024 | 18.73 Mn |
| Dec 31, 2023 | 8.07 Mn |
| Dec 31, 2023 | 8.07 Mn |